导读： 近日，清华大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出22项仪器设备采购意向，预算 总额达1.48亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，清华大学发2 2项仪器设备采购意向，预算总额达1 . 4 8亿元，涉及光谱仪总装、激光闪光光解光谱仪、台式X射线 吸收精细结构谱仪、共聚焦污染物毒性分析仪、多功能酶标仪、荧光定量核酸扩增仪等，预计采购时间为2 0 2 5年6~9 月。 | | | | 采 | | --- | --- | --- | --- | | 采购 | 需求概况 | 预算 | 购 | | 项目 | | 万元 | 时 | | | | | 间 | | | | | 202 | | 光谱仪总 | | | 5 | | 装 | 光谱仪总装 | 10000 | 年 | | | | | 6 月 | | | | | 202 | | 智能驾驶 | | | 5 | | 仿真系统 | 智能驾驶仿真系统 | 125 | 年 | | | | | 9 | | | | | 月 | | | | | 202 | ...

Core Insights - The global scientific instrument industry reported a total net profit of 19.8 billion yuan from 21 listed companies in 2024, showing a slight decline year-on-year, with the average net profit margin dropping to 11.6% from 15.7% in 2023, indicating a slowdown in industry growth and increasing strategic differentiation among companies [1][2]. Group 1: Financial Performance - The top three companies maintained their positions, with Thermo Fisher leading with a net profit of 6.33 billion USD, a profit margin of 14.8%, driven by a decrease in sales costs and an increase in gross profit margin [5]. - Danaher and Merck, while retaining their second and third positions, faced challenges with Danaher's net profit declining for two consecutive years due to a drop in the biotechnology segment, while Merck managed a slight profit decrease of 1.7% through market expansion in emerging regions [5][6]. - Among the 21 companies, 10 had net profit margins significantly above the industry average of 11.6%, highlighting the profitability efficiency of leading firms [8]. Group 2: Strategic Adjustments - Companies like SIBAT and Sartorius showed remarkable performance, with SIBAT achieving a 60.79% increase in net profit despite a 10% revenue decline, demonstrating effective cost control strategies [6]. - Sartorius experienced a 46.1% increase in net profit, attributed to a 16% revenue growth in the North American market and strategic focus on energy measurement [6]. - Agilent, despite a slight revenue decline, successfully implemented cost reduction strategies, resulting in a record high net profit and an improved global ranking [6]. Group 3: Challenges and Market Dynamics - Nine companies, including Zeiss and Veralto, faced profit declines despite revenue growth due to factors like currency fluctuations and rising costs [9]. - Companies such as Illumina and Bio-Rad encountered dual declines in revenue and profit, with Illumina suffering from goodwill impairment and Bio-Rad facing increased restructuring costs [9]. - The industry is experiencing structural adjustments, with emerging markets like Latin America and the Middle East driving growth for some companies, while the Chinese market presents challenges [10]. Group 4: Future Outlook - The ability of Thermo Fisher to return to peak profitability, the effectiveness of Danaher's cost-saving initiatives, and Sartorius's growth potential in energy measurement will be key indicators for the industry's direction [10]. - Companies must address the challenge of achieving sustainable growth through technological innovation, market rebalancing, and operational efficiency amidst overall profit margin pressures [10].

Core Viewpoint - The article highlights the procurement intentions of Central South University’s innovation platform, with a total budget of 191.579 million yuan for various advanced scientific instruments, expected to be purchased between July and December 2025 [1][2]. Procurement Overview - The procurement includes a range of sophisticated instruments such as: - Ultraviolet-visible near-infrared quantum efficiency tester (112.86 million yuan) [3] - Three-dimensional reconstruction focused ion beam electron microscope (1.3 billion yuan) [4] - High-sensitivity photoelectric and electro-optical conversion quantum efficiency tester (980 million yuan) [4] - Energy loss tester (283 million yuan) [4] - Various testing machines for mechanical properties, including high-temperature creep relaxation testing machines and electronic fatigue testing machines [3][4]. Budget Allocation - The total budget of 191.579 million yuan is allocated across multiple projects, with significant amounts dedicated to: - High-temperature and low-temperature testing equipment [3][4] - Advanced imaging systems such as X-ray fluorescence spectrometers and electron microscopes [4][5]. Expected Procurement Timeline - The expected procurement period is set for July to December 2025, indicating a strategic planning phase for the university's research capabilities [2][3]. Instrument Specifications - Specific instruments listed for procurement include: - Multi-field coupled low-field nuclear magnetic imaging system (450 million yuan) [4] - Soft X-ray electron probe analysis system (800 million yuan) [5] - Glow discharge mass spectrometer (970 million yuan) [5]. Conclusion - The procurement initiative reflects Central South University's commitment to enhancing its research infrastructure through significant investments in advanced scientific instruments, which may present opportunities for suppliers and manufacturers in the scientific equipment sector [1][2].

Core Viewpoint - The article emphasizes the growing importance of mass spectrometry technology in clinical diagnostics, driven by the need for earlier detection, more precise diagnosis, and comprehensive evaluation in the context of precision medicine and individualized treatment [1]. Group 1: Industry Trends - The trend in clinical diagnostics is moving towards "earlier detection, more precise diagnosis, and comprehensive evaluation," which aligns with the advancements in precision medicine [1]. - Mass spectrometry is recognized for its high sensitivity, specificity, and capability for simultaneous detection of multiple components, making it a key technology in the transformation of clinical testing [1]. Group 2: Clinical Applications - Mass spectrometry has been widely applied for the precise detection of small molecules and is gradually expanding into the detection of larger biomolecules such as proteins, peptides, and nucleic acids [1]. - The technology supports early disease screening, subtype diagnosis, and efficacy evaluation, providing reliable technical support for clinical applications [1]. Group 3: Upcoming Event - A network seminar titled "Fourth Clinical Mass Spectrometry Technology and Application Progress" is scheduled for June 12, 2025, organized by Instrument Information Network, to discuss the future development paths of clinical mass spectrometry [2][3].

导读： 本文深度聚焦国内50家上市仪器公司，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创新图谱。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 科学仪器，被誉为现代工业的"隐形基石"和科技创新的"眼睛与双手"。从基础研究到产业升级，从实验室探索到高端制造，仪器的精度与可靠 性直接决定着科研的高度与产业的质量。然而，这一关键领域曾长期被国际巨头垄断，国产仪器的"卡脖子"之痛，不仅关乎企业生存，更牵系 国家科技自主的战略安全。 近年来，政策东风频吹——从"十四五"规划的顶层设计，到财政专项的精准滴灌；从进口替代的硬性指标，到产学研协同的技术攻坚，国产科 学仪器行业正迎来前所未有的历史性机遇。在这场必须打赢的"逆袭战"中，研发投入成为企业竞争力的核心标尺：唯有真金白银砸向创新，才 能突破技术壁垒；唯有顶尖人才汇聚，方能锻造出与进口品牌抗衡的"中国精度"。 基于此，仪器信息网深度聚焦国内50家上市仪器企业，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创 新图谱。我们试图回答：谁在引 ...

Core Viewpoint - The issuance of the first prescription for mesenchymal stem cell drugs marks a significant breakthrough in the clinical application of stem cell therapies in China, transitioning from research achievements to accessible treatments [1]. Group 1: Clinical Application of Stem Cell Therapy - On June 5, 2025, the first prescription for a marketed mesenchymal stem cell drug was issued by a team led by Academician Huang Xiaojun at Peking University People's Hospital for a patient undergoing haploidentical transplantation [1]. - The first stem cell therapy drug, Aimi Maito Sai injection (Ruibo Sheng), received conditional approval from NMPA on January 2, 2025, targeting acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation [1]. - This innovative therapy utilizes human umbilical mesenchymal stem cells to regulate T-cell overactivation and inflammatory cytokine storms, providing a new solution for life-threatening immune attacks affecting multiple organs [1]. Group 2: Development of Health Industry in Jiangxi - Jiangxi's Ganjiang New Area is focusing on the life and health industry, aiming to enhance the industrial chain by integrating research and application, forming a cluster that includes traditional Chinese medicine, medical devices, beauty health products, and biomedicine [1]. - Antu Bio, a leading company in the in vitro diagnostics field, is collaborating with the Ganjiang New Area to leverage its strong research capabilities and advanced core technologies to maintain its leading position in the industry [1]. - The partnership aims to promote the deep integration of innovation chains, industrial chains, financial chains, and talent chains, establishing a modern industrial system with distinctive advantages [1]. Group 3: Strategic Positioning of Ganjiang New Area - Ganjiang New Area is recognized as a national-level new area, serving as a comprehensive functional platform with unique policy integration advantages and a conducive industrial development environment [2]. - The area is positioned to become a "bridgehead" and frontier for the high-end development of the in vitro diagnostics industry in Jiangxi Province [2]. - The collaboration with Antu Bio is expected to initiate high-standard and efficient development in artificial intelligence and smart testing systems [3].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 6月7日在第十一期"浦江科学大师讲坛"上，复旦大学法医学与法庭科学学院揭牌成立。国际 著名法庭科学鉴识专家李昌钰，复旦大学校长、中国科学院院士金力等为该学院揭牌。 据悉，新成立的法医学与法庭科学学院致力于培养具备家国情怀、社会责任感、全球视野、创 新能力与团队精神的高层次、复合型、应用型专业人才，建设成为国内领先、国际一流的法医 学与法庭科学创新高地。金力为李昌钰颁发复旦大学名誉教授证书，李昌钰将为法医学与法庭 科学学院的建设和发展提供宝贵支持和重要助力。 2022年9月，国务院学位委员会、教育部正式将法医学列为一级学科，标志着该学科迈入全新 发展阶段。 复旦大学是中国最早设立法医学专业的高校之一。去年1月，复旦大学设立法庭科学研究院， 围绕医理工文交叉融合，积极探索服务国家治理体系现代化的创新路径，一年多来已取得明显 成效。 今年5月，为进一步提升学校服务全面依法治国重大战略的能力，培养具有全球视野与创新能 力的法医学和法庭科学拔尖人才，复旦大学在法医学系基础上，整合法庭科学研究院 ...

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 6月11日，教育部官方发布关于拟同意设置本科高等学校的公示。公示称，拟同意设置 大湾区 大学等10所学校 。 大湾区大学是由广东省人民政府举办，东莞市政府投入保障为主的公办普通高等学校。学校有 两个校区，总面积2350亩。其中松山湖校区250亩、滨海湾校区2100亩。 学校立足粤港澳大湾区，面向全中国，辐射全世界，以理工为主、精理强工，致力于办成一 所"国际水准、开放包容、湾区特色"，能引领未来科技发展、产业升级和社会进步的 新型研 究型大学 。据悉，该校拟于 今年夏季高考开启本科招生 。 大湾区大学 （筹） 设有4个学院： 物质科学学院、理学院、信息科学技术学院、先进工程学 院 。 物质科学学院研究方向： 初步计划布局"材料科学与工程""物理学""电子科学与技术"三个方 向学科。本科教学率先开设"材料科学与工程""物理学"专业。 理学院 研究方向： 设有3个系，分别为数学系、物理系、化学系。 绿色能源与可持续工程。规划和建设能源动力一级学科，重点发展可持续能源、新能源科学与 工程、 ...

导读： 近日，康复大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出4项仪器设备采购意向，预算 总额达1.38亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，康复大学发布4项仪器设备采购意向，预算总额达1.38亿元，涉及神经科学专业教学实践创新平台、生理信号采 集分析系统、便携主动式红外动作捕捉系统、车床类机械加工设备等，预计采购时间为2025年6~11月。 康复大学 2 0 2 5年6 ~ 11 月 仪器设备采购 意向汇总表 | 采购项目 | 需求概况 | 采 预算 购 | | --- | --- | --- | | | | 时 万元 | | | | 间 | | | 拟采购神经科学专业教学实践创新平台设备，为满足学校教学需求，全面提升康复大学神经科学专业人才培养质量，建设支撑基础-应 | | | 神经科学 | 用-创新一体化的实践教学体系，需采购神经科学专业教学实践创新平台设备一宗，本项目将围绕神经科学专业核心课程与实验内容， | 202 | | 专业教学 | 配置涵盖分子细胞神经生物学、脑功能成像与 ...

Core Viewpoint - The revenue of 14 companies in the life sciences sector shows a "7 increase and 7 decrease" pattern, indicating a recovery trend in the industry as most companies have narrowed their revenue decline compared to 2023 [1][4]. Revenue Performance Summary - In 2024, the revenue of Shunyi Optical reached 38.295 billion yuan, a year-on-year increase of 20.87%, while its optical instrument business saw a decline of 18.4% [3][8]. - Mindray Medical reported a revenue of 36.726 billion yuan, a growth of 5.14%, with its in vitro diagnostics segment achieving a revenue of 13.765 billion yuan, up 10.82% [3][10]. - Antu Bio achieved a revenue of 4.471 billion yuan, a slight increase of 0.62% [3][10]. - The revenue of Tailin Bio was 349 million yuan, marking a significant increase of 29.33%, driven primarily by the pharmaceutical industry [3][7]. Sector-Specific Insights - In the sequencing instrument sector, BGI Genomics achieved a revenue of 3.012 billion yuan, with a notable increase in sales volume of nearly 1,270 units, representing a 48.59% year-on-year growth [4][5]. - The low-temperature storage sector showed signs of stabilization, with Haier Bio's revenue at 2.283 billion yuan, a slight increase of 0.13% [6]. - The optical microscope sector faced challenges, with several companies reporting declines in revenue, including Micron Optics with a revenue of 1.354 billion yuan, down 0.86% [8][9]. Declining Companies - New Zhi Bio reported a revenue of 168 million yuan, a decrease of 11.90%, while BoXun Bio's revenue fell to 122 million yuan, down 14.14% [9]. - Yirui Bio's revenue was 224 million yuan, reflecting a decline of 11.75% [9]. IVD Market Overview - The IVD market in China grew from 43 billion yuan in 2016 to 118.5 billion yuan in 2023, with a compound annual growth rate of 15.58% [10].